Posted by Michael Wonder on 22 Mar 2022
Valeo Pharma secures additional public reimbursement for Redesca, Enerzair Breezhaler and Atectura Breezhaler
22 March 2022 - Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia.
Valeo Pharma today announced that it has successfully entered into a Product Listing Agreement with the British Columbia Minister of Health, for the listing and public reimbursement of Redesca and Redesca HP, its low molecular weight heparin biosimilar for the prevention and treatment of thromboembolic disorders, on the British Columbia PharmaCare list of medications, effective today.
The Company also announces that its two innovative asthma therapies; Enerzair Breezhaler and Atectura Breezhaler, have also been accepted for public reimbursement by the Saskatchewan Drug Plan and the Prince Edward Island Pharmacare Drug Plan. The public reimbursement is currently in effect in Saskatchewan with the Prince Edward Island listing taking effect on 28 March 2022.
